Skip to main content
. 2019 Aug 24;26(3):1499–1510. doi: 10.1007/s12253-019-00726-w

Table 2.

Relationship between the clinicopathological characteristics and the expression of cell-cycle markers in core biopsy specimens

Feature (No. of tumors) Ki-67 mean MCM2 mean Cyclin A mean PHH3 mean
Clinical T categories
  T1 (5) 70.00 70.00 43.00 16.00
  T2 (39) 48.52 55.38 24.59 8.38
  T3 (5) 46.00 50.00 20.00 6.00
  T4 (12) 31.66 16.67 16.67 8.34
  p value 0.2157 0.0225 0.0830 0.0468
Clinical N categories
  N0 (21) 42.86 49.29 21.52 8.43
  N1–3 (31) 53.77 57.26 28.13 9.19
  p value 0.1366 0.2578 0.2135 0.3739
Histology *
  IDC (48) 50.98 55.00 26.39 9.17
  other (4) 30.00 42.50 14.25 5.50
Nuclear grade
  II (20) 32.60 38.35 17.20 6.85
  III (32) 59.84 63.91 30.63 10.63
  p value <0.0001 <0.0001 0.0003 0.0424
ER status
  positive (33) 37.33 45.61 19.97 7.64
  negative (19) 70.26 68.68 35.00 11.05
  p value <0.0001 0.0003 0.0011 0.0544
PR status
  positive (30) 36.90 46.83 19.47 7.83
  negative (22) 66.36 66.86 33.64 10.32
  p value <0.0001 0.0089 0.0013 0.1691
Her2 status
  positive (21) 47.86 50.00 24.52 8.67
  negative (31) 50.39 56.77 26.09 9.03
  p value 0.8245 0.2500 0.9558 0.7958
Triple negativity
  no (40) 41.30 47.63 12.72 7.55
  yes (12) 76.25 75.42 37.92 13.34
  p value <0.0001 <0.0001 0.0046 0.0053
Biological subtype
  Luminal A (7) 19.57 37.14 8.43 4.71
  Lum.B-prolif. (12) 42.50 49.58 24.58 7.25
  Lum.B-Her2 + (15) 41.66 48.00 21.00 9.13
  Her2-positive (6) 63.33 55.00 33.33 7.50
  Triple negative(12) 76.25 75.42 37.92 13.34
  p value <0.0001 0.0026 0.0004 0.0119
Tumor infiltrating lymphocytes (TIL)#
  TIL ≤ 1% (18) 38.33 46.67 21.61 7.61
  TIL 1–20% (19) 57.37 53.95 28.42 10.37
  TIL >20% (6) 60.00 58.33 34.17 7.17
  p value 0.0402 0.9676 0.4744 0.9970

Underlined: statistically significant difference

*due to low case numbers and statistical power we did not perform a statistical comparison

# missing in 9 patients